Insulin Lispro (Humalog) from Canada
Rapid-acting insulin analogue created by recombinant DNA technology with amino acid modifications for faster absorption. Falls under HTS 2937.12.00.00 as a structural analogue of insulin used primarily as a hormone for glycemic control. Qualifies as a chain-modified polypeptide hormone per chapter notes.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Submit FDA IND/BLA documentation; verify analogue structure matches declared sequence
• Use validated refrigerated shipping with temperature data loggers; insulin analogues are heat-sensitive
• Avoid bulk packaging declarations; pure API form stays in 2937, finished injectables move to 3004